Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/54531
Title: Prediction of progression-free survival in patients with advanced, well-differentiated, neuroendocrine tumors being treated with a somatostatin analog: The GETNE-TRASGU study
Authors: 
Filiation: Servicio de Anatomía Patológica. Hospital Universitario de Fuenlabrada
Mesh: 
Decs: 
Issue Date: 2019
Citation: Carmona Bayonas A, Jiménez-Fonseca P, Lamarca A, Barriuso J, Castaño Pascual A, Benavent M, et al. Prediction of progression-free survival in patients with advanced, well-differentiated, neuroendocrine tumors being treated with a somatostatin analog: The GETNE-TRASGU Study. J Clin Oncol. 2019;37(28):2571-80.
Abstract: Somatostatin analogs (SSAs) are recommended for the first-line treatment of most patients with well-differentiated, gastroenteropancreatic (GEP) neuroendocrine tumors; however, benefit from treatment is heterogeneous. The aim of the current study was to develop and validate a progression-free survival (PFS) prediction model in SSA-treated patients.
PMID: 31390276
URI: https://hdl.handle.net/20.500.12530/54531
Rights: info:eu-repo/semantics/openAccess
Appears in Collections:Hospitales > H. U. de Fuenlabrada > Artículos

Files in This Item:
File Description SizeFormat 
J Clin Oncol.pdf565.19 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons